Patent ID: 8377979
Filing Date: 2013-02-19
Classification: A61K,A61P

Abstract:
1. A pharmaceutical formulation of phenytoin sodium comprising a dry blended powder in a capsule having from about 10% (w/w) to about 90% (w/w) phenytoin sodium, from 6% (w/w) to 20% (w/w) magnesium stearate and from about 1% (w/w) to about 7% (w/w) of a hydrophilic polymer, and wherein the in vitro dissolution profile for phenytoin sodium when tested using USP apparatus I in water at 75 rpm is: (i) from about 20% (w/w) to about 40% (w/w) released in 30 minutes; (ii) from about 40% (w/w) to about 85% (w/w) released in 60 minutes; and (iii) not less than 70 percent (w/w) released in 120 minutes.